glp-1 receptor agonist and dpp-4 inhibitor combination not recommended with Clinical Use of Inhibitors Frontiers DPP-4 INHIBITORS - Dipeptidyl Peptidase-4

Annual cancer progression risk: 0.5% per person, per year (1 in 200) Five year risk for either HGD or cancer: 1.7% (1 in 59) Cells are beginning to grow abnormally, but not yet likely to become cancerous or spread Grading low-grade dysplasia can be very challenging, and pathologists often do not agree on the diagnosis

Do not self-medicate, especially with injectable or high-dose forms.

For patients chasing inflammation as part of aging, we may add a peptide like KPV that calms it from a different angle, again because one pathway alone gets compensated away

Nat Rev Dis Primers (2015) 1:15011

551,552,553 Finally ageing impairs the ability of astrocytes to mount protective reactive astrogliosis 120 thus limiting brain protection against pathological insults

Adipose tissue expansion in obesity, health, and disease